brentuximab vedotin: current status and future considerations for this agent in hl treatment
Published 1 year ago • 442 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
1:24
novel agents for the treatment of hodgkin lymphoma: brentuximab vedotin and nivolumab
-
1:04
updates on the use of brentuximab vedotin in later-stage hl
-
3:09
real-world efficacy of brentuximab vedotin as consolidation therapy in patients with hl
-
2:18
sgn35-027: brentuximab vedotin with nivolumab, doxorubicin, and dacarbazine in hl
-
3:07
current indications for the use of brentuximab vedotin in hodgkin lymphoma
-
1:27
treatment options for patients with hodgkin lymphoma who progress after brentuximab vedotin
-
2:39
an update on the cobra trial: pet-response adapted treatment with brentuximab vedotin for hl
-
1:36
the promise of brentuximab vedotin for the treatment of pediatric hl
-
1:41
swog s1826: nivolumab avd vs brentuximab vedotin avd for advanced stage hodgkin lymphoma
-
1:08
nivolumab and brentuximab vedotin with or without bendamustine for r/r hodgkin lymphoma
-
1:55
the real-world efficacy of brentuximab vedotin consolidation post-autosct in r/r hl
-
2:36
brentuximab vedotin versus pembrolizumab in r/r classical hodgkin lymphoma
-
1:14
brentuximab vedotin combined with nivolumab for hodgkin lymphoma
-
3:23
brentuximab vedotin, nivolumab, doxorubicin & dacarbazine for early stage classical hodgkin lymphoma
-
2:20
nivolumab-avd vs brentuximab vedotin-avd in pediatric patients with chl: swog s1826 trial
-
2:30
brentuximab vedotin for ctcl
-
3:47
brentuximab vedotin plus chemotherapy prior to asct in r/r hodgkin lymphoma
-
2:44
brentuximab vedotin and chp for ptcl: upcoming phase ii trial
-
3:26
phase 2 trial of brentuximab vedotin plus avd for non-bulky limited-stage hodgkin lymphoma